中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2021, Vol. 16 ›› Issue (12): 2494-2498.doi: 10.4103/1673-5374.313062

• 原著:退行性病与再生 • 上一篇    下一篇

多发性硬化患者和健康对照11C-PK11195血浆代谢率相同

  

  • 出版日期:2021-12-15 发布日期:2021-05-15
  • 基金资助:

    GE Healthcare资金资助项目

11C-PK11195 plasma metabolization has the same rate in multiple sclerosis patients and healthy controls: a cross-sectional study

Aline Morais de Souza1, #, Milena Sales Pitombeira2, #, Larissa Estessi de Souza1, Fabio Luiz Navarro Marques1, Carlos Alberto Buchpiguel1, Caroline Cristiano Real1, Daniele de Paula Faria1, 2, *   

  1. 1Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; 2Department of Neurology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
  • Online:2021-12-15 Published:2021-05-15
  • Contact: Daniele de Paula Faria, PhD, danielefaria1@gmail.com.
  • Supported by:
    This work was supported by GE Healthcare, No. 12496139131 (to DPF and CAB). 

PDF

92

摘要：

正电子发射体示踪剂11C-PK11195用于神经炎性疾病研究中先天免疫细胞活化的正电子发射断层扫描（PET）成像。对于图像定量分析，有必要在成像采集过程中定量此示踪剂在动脉血浆中的代谢情况。研究目的在于比较健康对照组和多发性硬化患者的11C-PK11195血浆代谢率，并评估性别、年龄、治疗方法和疾病表型对动脉血浆中示踪剂代谢率的影响。应用高效液相色谱检测11C-PK11195注射后20，45和60min，多发性硬化患者（n = 50）和健康对照（n = 23）动脉血浆中11C-PK11195代谢率。结果显示，健康对照组和多发性硬化患者或性别、年龄、治疗方法和疾病表型分层后的血浆中11C-PK11195代谢率相似。总之，多发性硬化患者和健康对照者的11C-PK11195代谢率相同，不受性别，年龄，治疗方法和疾病表型的影响。因此，通过检测总体代谢率平均值，可以有助于在11C-PK11195 PET成像中免除示踪剂代谢的测定。

https://orcid.org/0000-0002-1766-2786 (Daniele de Paula Faria)

Abstract: 11C-PK11195 is a positron emitter tracer used for Positron Emission Tomography (PET) imaging of innate immune cell activation in studies of neuroinflammatory diseases. For the image quantitative analysis, it is necessary to quantify the intact fraction of this tracer in the arterial plasma during imaging acquisition (plasma intact fraction). Due to the complexity and costs involved in this analysis it is important to evaluate the real necessity of individual analysis in each 11C-PK11195 PET imaging acquisition. The purpose of this study is to compare 11C-PK11195 plasma metabolization rate between healthy controls and multiple sclerosis (MS) patients and evaluate the interference of sex, age, treatment, and disease phenotype in the tracer intact fraction measured in arterial plasma samples. 11C-PK11195 metabolization rate in arterial plasma was quantified by high performance liquid chromatography in samples from MS patients (n = 50) and healthy controls (n = 23) at 20, 45, and 60 minutes after 11C-PK11195 injection. Analyses were also stratified by sex, age, treatment type, and MS phenotype. The results showed no significant differences in the metabolization rate of healthy controls and MS patients, or in the stratified samples. In conclusion, 11C-PK11195 metabolization has the same rate in patients with MS and healthy controls, which is not affected by sex, age, treatment, and disease phenotype. Thus, these findings could contribute to exempting the necessity for tracer metabolization determination in all 11C-PK11195 PET imaging acquisition, by using a population metabolization rate average. The study procedures were approved by the Ethics Committee for Research Projects Analysis of the Hospital das Clinicas of the University of Sao Paulo Medical School (approval No. 624.065) on April 23, 2014.

Key words: 11C-PK11195, HPLC, kinetic modeling, metabolization, multiple sclerosis, neuroinflammation, PET imaging, PET tracer,  , radiometabolites

中图分类号: